{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:50:48Z","timestamp":1792680648555,"version":"4.5.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"Importance<\/jats:title>Prurigo nodularis (PN) is a debilitating skin disease characterized by intense pruritus and hyperkeratotic skin nodules. Nemolizumab, a monoclonal antibody targeting interleukin 31 receptor \u03b1, is a promising novel therapy for the treatment of moderate to severe PN. The biological mechanisms by which nemolizumab promotes improvement of itch and skin lesions in PN are unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To characterize changes in plasma protein biomarkers associated with clinical response to nemolizumab in patients with PN.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This multicenter cohort study included patients recruited from Austria, France, Germany, Poland, and the US from a phase 2 clinical trial. Adults diagnosed with moderate to severe PN with severe pruritus for at least 6 months were included in the original trial. Patients in the nemolizumab group were included in the present study if they achieved at least a 4-point decrease in the Peak Pruritus Numerical Rating Scale (PP-NRS) from baseline to week 12 during nemolizumab treatment. Placebo controls did not experience a 4-point decrease in PP-NRS. Mass spectrometry with tandem mass tags to enrich skin-specific protein detection was used to characterize changes in plasma protein expression in nemolizumab and placebo groups. Data were collected from November 2, 2017, to September 26, 2018, and analyzed from December 6, 2019, to April 8, 2022.<\/jats:p><\/jats:sec>Intervention<\/jats:title>As part of the clinical trial, patients were treated with 3 doses of nemolizumab or placebo at 0, 4, and 8 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Changes in plasma and epidermal protein expression in nemolizumab-treated patients compared with the placebo group at 0, 4, and 12 weeks.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the 38 patients included in the analysis (22 women and 16 men; mean [SD] age, 55.8 [15.8] years), enrichment analysis of canonical pathways, biological functions, and upstream regulators showed downregulation of terms involving inflammation (IL-6, acute-phase response, signal transducer and activator of transcription 3, and interferon \u03b3), neural processes (synaptogenesis signaling and neuritogenesis), tissue remodeling and fibrosis (transforming growth factor \u03b21 and endothelin-1), and epidermal differentiation (epithelial mesenchymal transition) in the plasma of nemolizumab group.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, differences between nemolizumab and placebo groups included modulation of inflammatory signaling, neural development, and epithelial differentiation, suggesting a promising potential approach for clinical management of PN.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.2609","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T15:01:18Z","timestamp":1691593278000},"page":"977","source":"Crossref","is-referenced-by-count":26,"title":["Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab"],"prefix":"10.1001","volume":"159","author":[{"given":"Junwen","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Parthasarathy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah L.","family":"Cornman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Kambala","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madan M.","family":"Kwatra","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Center for Chronic Pruritus, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Piketty","sequence":"additional","affiliation":[{"name":"Galderma SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Chaskar","sequence":"additional","affiliation":[{"name":"Galderma SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayendra Kumar","family":"Krishnaswamy","sequence":"additional","affiliation":[{"name":"Galderma SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Julia","sequence":"additional","affiliation":[{"name":"Galderma SA, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"doi230034r1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","article-title":"Prurigo nodularis: epidemiology and clinical features.","volume":"83","author":"Huang","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"doi230034r2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMe1916733","article-title":"Breaking the itch-scratch cycle in prurigo nodularis.","volume":"382","author":"Kwatra","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"doi230034r3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2021.05.036","article-title":"Health-related quality of life and economic burden of prurigo nodularis.","volume":"86","author":"Whang","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"doi230034r4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/ced.v46.7","article-title":"Clinical characteristics and disease burden in prurigo nodularis.","volume":"46","author":"Aggarwal","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"doi230034r5","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/jdv.v34.10","article-title":"Chronic nodular prurigo: clinical profile and burden: a European cross-sectional study.","volume":"34","author":"Pereira","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi230034r6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2018.04.044","article-title":"Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial.","volume":"79","author":"Steinke","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi230034r7","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: pathogenesis and management.","volume":"83","author":"Williams","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi230034r8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/17512433.2021.1852080","article-title":"Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.","volume":"14","author":"Williams","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"doi230034r9","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40265-021-01521-1","article-title":"IL-31 Inhibition as a therapeutic approach for the management of chronic pruritic dermatoses.","volume":"81","author":"Roh","year":"2021","journal-title":"Drugs"},{"issue":"9","key":"doi230034r10","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.jid.2021.02.749","article-title":"Prurigo nodularis is characterized by systemic and cutaneous T helper 22 immune polarization.","volume":"141","author":"Belzberg","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi230034r11","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jid.2021.10.011","article-title":"Cluster analysis of circulating plasma biomarkers in prurigo nodularis reveals a distinct systemic inflammatory signature in African Americans.","volume":"142","author":"Sutaria","year":"2022","journal-title":"J Invest Dermatol"},{"key":"doi230034r12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1011142","article-title":"Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: a cluster analysis.","volume":"9","author":"Parthasarathy","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"doi230034r13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1034\/j.1600-0560.2000.027007359.x","article-title":"CGRP-immunoreactive nerves in prurigo nodularis\u2014an exploration of neurogenic inflammation.","volume":"27","author":"Liang","year":"2000","journal-title":"J Cutan Pathol"},{"issue":"6","key":"doi230034r14","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.jaci.2022.02.021","article-title":"Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo.","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"doi230034r15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1022889","article-title":"Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis.","volume":"9","author":"Deng","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"doi230034r16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jid.2022.08.042","article-title":"Transcriptomic, epigenomic, and neuroanatomic signatures differ in chronic prurigo, atopic dermatitis, and brachioradial pruritus.","volume":"143","author":"Agelopoulos","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"8","key":"doi230034r17","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/jdv.13406","article-title":"Increased angiogenesis and VEGF expression correlates with disease severity in prurigo patients.","volume":"30","author":"Krull","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"doi230034r18","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.jid.2022.02.010","article-title":"Cutaneous transcriptomics identifies fibroproliferative and neurovascular gene dysregulation in prurigo nodularis compared with psoriasis and atopic dermatitis.","volume":"142","author":"Sutaria","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi230034r19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/cup.2010.37.issue-5","article-title":"Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients.","volume":"37","author":"Weigelt","year":"2010","journal-title":"J Cutan Pathol"},{"issue":"8","key":"doi230034r20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis.","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med"},{"key":"doi230034r21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.639097","article-title":"Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues.","volume":"8","author":"Nemmer","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"doi230034r22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/exd.v30.issue-6","article-title":"Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta.","volume":"30","author":"Hashimoto","year":"2021","journal-title":"Exp Dermatol"},{"issue":"20","key":"doi230034r23","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"doi230034r24","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jaci.2021.10.004","article-title":"Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.","volume":"149","author":"Tsoi","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"doi230034r25","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24137","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis.","volume":"2","author":"Bao","year":"2013","journal-title":"JAKSTAT"},{"issue":"6","key":"doi230034r26","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1172\/JCI67323","article-title":"Neural peptidase endothelin-converting enzyme 1 regulates endothelin 1\u2013induced pruritus.","volume":"124","author":"Kido-Nakahara","year":"2014","journal-title":"J Clin Invest"},{"issue":"3","key":"doi230034r27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jid.2019.08.438","article-title":"IL-17A induces endothelin-1 expression through p38 pathway in prurigo nodularis.","volume":"140","author":"Wong","year":"2020","journal-title":"J Invest Dermatol"},{"key":"doi230034r28","doi-asserted-by":"publisher","DOI":"10.1177\/2058738420907186","article-title":"A potential inflammatory role of IL-31 in psoriatic arthritis: a correlation with Th17 cytokine profile.","volume":"34","author":"Bautista-Herrera","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"key":"doi230034r30","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3389\/fimmu.2017.00873","article-title":"The role of interferons in inflammation and inflammasome activation.","volume":"8","author":"Kopitar-Jerala","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"doi230034r31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ejp.767","article-title":"The pathogenesis of prurigo nodularis\u2014\"super-itch\u201d in exploration.","volume":"20","author":"Zeidler","year":"2016","journal-title":"Eur J Pain"},{"issue":"3","key":"doi230034r32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/exd.2008.17.issue-3","article-title":"Neurophysiological and neurochemical basis of modern pruritus treatment.","volume":"17","author":"St\u00e4nder","year":"2008","journal-title":"Exp Dermatol"},{"issue":"2","key":"doi230034r33","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell\u2013dependent itch: involvement of TRPV1 and TRPA1.","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"doi230034r34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/bjd.2011.165.issue-1","article-title":"Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy.","volume":"165","author":"Schuhknecht","year":"2011","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi230034r35","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41467-017-01488-2","article-title":"Injury-activated glial cells promote wound healing of the adult skin in mice.","volume":"9","author":"Parfejevs","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"doi230034r36","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/sj.jid.5701184","article-title":"The epidermal growth factor receptor system in skin repair and inflammation.","volume":"128","author":"Pastore","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi230034r37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/08977194.2011.595714","article-title":"TGF-\u00df signaling in fibrosis.","volume":"29","author":"Biernacka","year":"2011","journal-title":"Growth Factors"},{"issue":"7","key":"doi230034r38","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Dysregulation of transforming growth factor \u00df signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts.","volume":"46","author":"Leask","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"doi230034r39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00000637-199943020-00013","article-title":"Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids.","volume":"43","author":"Lee","year":"1999","journal-title":"Ann Plast Surg"},{"issue":"4","key":"doi230034r40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.coph.2009.04.008","article-title":"Anti-inflammatory and pro-inflammatory roles of TGF-\u00df, IL-10, and IL-22 in immunity and autoimmunity.","volume":"9","author":"Sanjabi","year":"2009","journal-title":"Curr Opin Pharmacol"},{"issue":"7090","key":"doi230034r41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"issue":"12","key":"doi230034r42","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ni.1659","article-title":"Transforming growth factor-\u00df \u201creprograms\u201d the differentiation of T helper 2 cells and promotes an interleukin 9\u2013producing subset.","volume":"9","author":"Veldhoen","year":"2008","journal-title":"Nat Immunol"},{"issue":"7","key":"doi230034r43","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3390\/cells10071587","article-title":"Epithelial-mesenchymal transition (EMT): the type-2 EMT in wound healing, tissue regeneration and organ fibrosis.","volume":"10","author":"Marconi","year":"2021","journal-title":"Cells"},{"issue":"5","key":"doi230034r44","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jaad.2023.01.042","article-title":"The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: a cluster analysis.","volume":"88","author":"Parthasarathy","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"doi230034r29","volume-title":"Physiology, Acute Phase Reactants","author":"Gulhar","year":"2022"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2808308\/jamadermatology_deng_2023_oi_230034_1695075684.57845.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T15:14:26Z","timestamp":1695222866000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2808308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.2609","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}